We participate in numerous events promoting our portfolio companies and meeting our clients.


RhoVac AB, a Ventac portfolio company, announced that the Danish Medicines Agency and the Ethics Committee issued their respective approvals to RhoVac’s application to initiate its first clinical study. The planned phase I / II trial will be an open study including approximately 20 patients diagnosed with metastatic cancer. For more information, please follow this link (in Swedish).

Subscribe to our Newsletter

Thank you!